IVERIC bio, Inc. (ISEE) Stock Analysis
DELISTED 2023
What happened to IVERIC bio, Inc. (ISEE) stock?
IVERIC bio, Inc. (ISEE) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IVERIC bio, Inc. (ISEE) trades at $39.95. IVERIC bio, Inc. is a biopharmaceutical company focused on developing treatments for retinal diseases. Their lead product, Zimura, targets geographic atrophy secondary to dry age-related macular degeneration. Market cap: $5.51B, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for ISEE: ISEE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ISEE against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ISEE: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →IVERIC bio, Inc. (ISEE) Healthcare & Pipeline Overview
IVERIC bio, Inc. specializes in developing novel treatments for retinal diseases, with a focus on age-related and orphan inherited conditions. Their lead candidate, Zimura, targets geographic atrophy secondary to dry age-related macular degeneration, positioning them in the competitive biotechnology sector.
What Is the Investment Thesis for ISEE?
IVERIC bio, Inc. presents a compelling investment thesis centered on its lead drug candidate, Zimura, and its potential to address the significant unmet need in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Positive results from the GATHER2 Phase 3 clinical trial could serve as a major catalyst, driving significant shareholder value. The company's focus on orphan inherited retinal diseases (IRDs) provides additional growth opportunities, leveraging the potential for accelerated regulatory pathways and market exclusivity. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing therapies for retinal diseases. With a market capitalization of $5.51B and a beta of 1.10, IVERIC bio represents a high-growth, high-risk investment opportunity within the biotechnology sector.
Based on FMP financials and quantitative analysis
ISEE Key Highlights
Zimura is in Phase 3 clinical trial (GATHER2) for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
- STAR (OPH2005) is in Phase 2b clinical trial for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
- IVERIC bio has a market capitalization of $5.51B.
- The company's pipeline includes IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA and other age-related retinal diseases.
- IVERIC bio focuses on both age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs).
Who Are ISEE's Competitors?
ISEE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LHCG LHC Group, Inc. | $169.81 | +0.00% | $5.29B | 45 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| CBAY CymaBay Therapeutics | $32.48 | +0.03% | $3.73B | 59 |
| LGND Ligand Pharmaceuticals Incorporated | $287.39 | -1.14% | $5.76B | 94 |
| ACAD ACADIA Pharmaceuticals Inc. | $29.15 | -3.51% | $4.99B | 89 |
| LQDA Liquidia Corporation | $71.05 | -5.68% | $6.32B | 99 |
| ORKA Oruka Therapeutics, Inc. | $104.86 | -4.40% | $6.32B | 75 |
| REGMF RemeGen Co., Ltd. | $12.05 | +0.00% | $6.79B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ISEE's Key Strengths?
Strong pipeline of product candidates targeting retinal diseases.
- Lead product candidate, Zimura, has shown promising clinical results.
- Focus on both age-related and orphan inherited retinal diseases.
- Experienced management team with expertise in drug development and commercialization.
What Are ISEE's Weaknesses?
Reliance on the success of Zimura.
- High cash burn rate associated with clinical trials.
- Limited commercial infrastructure.
- Competition from larger pharmaceutical companies.
What Could Drive ISEE Stock Higher?
ISEE catalyst: Results from the GATHER2 Phase 3 clinical trial of Zimura for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
- Enrollment and progress in the Phase 2b clinical trial of STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
- Advancement of IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, through preclinical and clinical development.
- Potential for strategic partnerships or acquisitions to expand the company's pipeline and market reach.
What Are the Key Risks for ISEE?
Negative return on equity (-39.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Zimura or other product candidates.
- Regulatory setbacks in obtaining approval for Zimura or other product candidates.
- Competition from other companies developing therapies for retinal diseases.
- Patent challenges to the company's intellectual property.
- High cash burn rate associated with clinical trials and research and development activities.
What Are the Growth Opportunities for ISEE?
- Expansion of Zimura into Additional Indications: IVERIC bio has the opportunity to expand the use of Zimura beyond geographic atrophy (GA) to treat other complement-mediated retinal diseases. This could significantly increase the addressable market for Zimura and drive revenue growth. The market size for complement-mediated retinal diseases is estimated to be substantial, with potential for multi-billion dollar sales. Timeline for expansion would depend on clinical trial results and regulatory approvals.
- Advancement of STAR (OPH2005) for LCA10 and STGD1: The successful development and commercialization of STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1) represents a significant growth opportunity. These are orphan inherited retinal diseases with limited treatment options, offering the potential for accelerated regulatory pathways and premium pricing. The market size for LCA10 and STGD1 treatments is estimated to be in the hundreds of millions of dollars.
- Development of IC-500 for GA and Other Age-Related Retinal Diseases: IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, has the potential to address a broader range of age-related retinal diseases beyond GA. This could significantly expand IVERIC bio's market reach and revenue potential. The market for age-related retinal disease treatments is substantial and growing, driven by an aging global population.
- Strategic Partnerships and Acquisitions: IVERIC bio could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or enter new geographic markets. This could accelerate growth and diversify the company's revenue streams. The biotechnology industry is characterized by frequent M&A activity, offering numerous opportunities for IVERIC bio to enhance its competitive position.
- Geographic Expansion: IVERIC bio has the opportunity to expand its commercial operations beyond the United States to international markets. This could significantly increase the company's revenue potential and market share. The global market for retinal disease treatments is substantial, with significant growth opportunities in Europe and Asia.
What Are ISEE's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Specialized expertise in retinal disease research and development.
- Established clinical trial infrastructure and regulatory expertise.
- Strong relationships with key opinion leaders in the ophthalmology field.
What Does ISEE Do?
IVERIC bio, Inc., founded in 2007 and headquartered in Parsippany, New Jersey, is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for retinal diseases. The company focuses on both age-related macular degeneration (AMD) and a range of orphan inherited retinal diseases (IRDs). IVERIC bio's lead product candidate is Zimura, an inhibitor of complement factor C5, which is being developed for the treatment of geographic atrophy (GA) secondary to dry AMD. Zimura has undergone Phase 2/3 (GATHER1) and is currently in Phase 3 (GATHER2) clinical trials. Beyond Zimura, IVERIC bio has a pipeline of additional product candidates, including STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1), currently in Phase 2b clinical trial. They also have IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA, IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for IRDs associated with mutations in the BEST1 gene. The company also has discovery and research programs targeting LCA10, STGD1, and usher syndrome type 2A-Related IRDs. Formerly known as Ophthotech Corporation, IVERIC bio changed its name in April 2019 to reflect its expanded focus and pipeline.
What Products and Services Does ISEE Offer?
- Discovers and develops novel treatments for retinal diseases.
- Focuses on age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs).
- Develops Zimura, an inhibitor of complement factor C5 for geographic atrophy (GA).
- Develops STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
- Develops IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA and other age-related retinal diseases.
- Conducts discovery and research programs for LCA10, STGD1, and usher syndrome type 2A-Related IRDs.
How Does ISEE Make Money?
- Develops and patents novel therapeutic candidates for retinal diseases.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Commercializes approved products through its own sales force or partnerships.
What Industry Does ISEE Operate In?
The biotechnology industry is characterized by high growth potential driven by innovation and unmet medical needs, particularly in areas like retinal diseases. The market for AMD treatments is substantial and growing, fueled by an aging global population. IVERIC bio operates in a competitive landscape that includes companies like LHCG: LHC Group, Inc., MRTX: Mirati Therapeutics, Inc., and CBAY: CymaBay Therapeutics, all vying for market share in various therapeutic areas. The success of IVERIC bio depends on its ability to navigate regulatory hurdles, demonstrate clinical efficacy, and secure market access for its products.
Who Are ISEE's Key Customers?
- Patients with age-related macular degeneration (AMD).
- Patients with orphan inherited retinal diseases (IRDs).
- Ophthalmologists and retinal specialists.
- Hospitals and clinics.
Company Profile
IVERIC bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Glenn P. Sblendorio. ISEE has traded publicly since 2013.
How IVERIC bio, Inc. Is Valued
IVERIC bio, Inc. carries a market capitalization of $5.51B, placing it in the mid-cap category.
Key Financial Metrics
Return on equity for IVERIC bio, Inc. stands at -39.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
IVERIC bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 22.04 places it in the safe zone, indicating low near-term bankruptcy risk.
ISEE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in IVERIC's potential, indicating that those closest to the company believe in its future.
- Community sentiment has shifted positively, with discussions highlighting advancements in their clinical trials and product pipeline.
- Analysts have noted strong interest in IVERIC's innovative therapies, which could address unmet medical needs in the ophthalmology sector.
- Recent partnerships and collaborations have bolstered market perception, signaling that industry players see value in IVERIC's offerings.
Bear Case
- Concerns around regulatory approvals have surfaced, leading to skepticism about the timeline for product launches and market entry.
- Social sentiment has shown some volatility, with discussions reflecting uncertainty over the competitive landscape in the biotech field.
- Recent market developments have raised questions about funding and financial sustainability, creating hesitation among investors.
- A bearish narrative has emerged from some community members focusing on potential delays in clinical trial results, which could impact investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ISEE Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Dec 13, 2019
Leadership: Glenn P. Sblendorio
CEO
Glenn P. Sblendorio has extensive experience in the biopharmaceutical industry, with a proven track record of leading and growing companies. Prior to joining IVERIC bio, he held leadership positions at several other biopharmaceutical companies, including The Medicines Company and চোখের Corporation. He has a strong background in finance, operations, and business development. Sblendorio's experience spans various therapeutic areas, including cardiovascular disease and ophthalmology. His expertise in strategic planning and execution has been instrumental in driving growth and creating shareholder value.
Track Record: Under Glenn P. Sblendorio's leadership, IVERIC bio has made significant progress in advancing its pipeline of product candidates, particularly Zimura. He has overseen the successful completion of Phase 2/3 clinical trials for Zimura and the initiation of Phase 3 trials. Sblendorio has also been instrumental in securing funding for the company's research and development programs and expanding its strategic partnerships. He manages 163 employees.
ISEE Healthcare Stock FAQ
What happened to IVERIC bio, Inc. (ISEE) stock?
IVERIC bio, Inc. (ISEE) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
Can I still buy ISEE shares?
No. ISEE stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for ISEE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ISEE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to IVERIC bio, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does IVERIC bio, Inc. do?
IVERIC bio, Inc. is a biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases, with a particular emphasis on age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs). Their lead product candidate, Zimura, is being developed for the treatment of geographic atrophy (GA) secondary to dry AMD.
What do analysts say about ISEE stock?
Analyst consensus on ISEE stock reflects the potential of Zimura in treating geographic atrophy (GA). Key valuation metrics include market capitalization and potential revenue projections based on Zimura's success. Growth considerations revolve around the successful completion of clinical trials, regulatory approvals, and market penetration.
What are the main risks for ISEE?
The main risks for ISEE include clinical trial failures, regulatory setbacks, competition from other companies developing therapies for retinal diseases, and patent challenges to the company's intellectual property. The success of IVERIC bio is heavily reliant on the successful development and commercialization of Zimura, and any setbacks in this area could significantly impact the company's stock price.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.